0000000000261673

AUTHOR

Nunzia Sapienza

showing 2 related works from this author

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

1990

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy…

AdultBlood Glucosemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyGastroenterologyInternal medicineDiabetes mellitusmedicineHumansInsulinImmunology and AllergyThymopentinChildGlycemicImmunity CellularC-Peptidebusiness.industryInsulinRemission InductionHemoglobin AReceptors Interleukin-2medicine.diseaseClinical trialTiterDiabetes Mellitus Type 1EndocrinologyChild PreschoolInsulin dependent diabetesMetabolic control analysisThymopentinbusinessmedicine.drugJournal of Autoimmunity
researchProduct

Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients

1989

In this study, we investigated whether an interleukin 2 (IL-2) secretion defect by peripheral blood mononuclear cells (PBMCs) after in vitro stimulation with phytohemagglutinin (PHA-M) occurs in either newly diagnosed or long-standing type I (insulin-dependent) diabetic patients and whether it is accompanied by a dysregulation of soluble IL-2— receptor (IL-2RS) production. PBMC cultures (2.5 × 106 cells), unstimulated or stimulated with PHA-M (25 μg/ml), from 20 type I diabetic patients (10 with time since onset <3 mo and 10 with long-term diabetes of <3 yr) and 10 control subjects were studied for the production of IL-2 and IL-2RS in their respective supernatants. No differen…

AdultMaleInterleukin 2medicine.medical_specialtyTime FactorsAdolescentEndocrinology Diabetes and MetabolismStimulationPeripheral blood mononuclear cellIn vivoInternal medicineInternal MedicinemedicineHumansSecretionPhytohemagglutininsChildReceptorCells Culturedbusiness.industryLymphokineReceptors Interleukin-2In vitroDiabetes Mellitus Type 1EndocrinologySolubilityLeukocytes MononuclearInterleukin-2Femalebusinessmedicine.drug
researchProduct